- HK$6.87bn
- HK$6.36bn
- CNY891.50m
- 48
- 10
- 27
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 32.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.01 | ||
| Price to Tang. Book | 3.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.24% | ||
| Return on Equity | -4.4% | ||
| Operating Margin | -5.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 677.83 | 1,200.32 | 1,696.74 | 3,756.2 | 891.5 | 979.55 | 1,089.74 | 8.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +44.31 | +83.65 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yunkang Group Ltd is a China-based Company mainly engaged in the provision of diagnosis testing services. The Company operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The Company primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 20th, 2018
- Public Since
- May 18th, 2022
- No. of Employees
- 1,510
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited- Shares in Issue
- 621,250,500
- Address
- No. 6 Lizhishan Road, GUANGZHOU
- Web
- http://www.yunkanghealth.com/
- Phone
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 2325
Similar to 2325
Adicon Holdings
Stock Exchange of Hong Kong Limited
Aidigong Maternal & Child Health
Stock Exchange of Hong Kong Limited
Aidigong Maternal & Child Health
Stock Exchange of Hong Kong Limited
Arrail
Stock Exchange of Hong Kong Limited
Suzhou Basecare Medical
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:25 UTC, shares in Yunkang are trading at HK$11.06. This share price information is delayed by 15 minutes.
Shares in Yunkang last closed at HK$11.06 and the price had moved by -22.22% over the past 365 days. In terms of relative price strength the Yunkang share price has underperformed the FTSE Developed Asia Pacific Index by -18.82% over the past year.
The overall consensus recommendation for Yunkang is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Yunkang does not currently pay a dividend.
Yunkang does not currently pay a dividend.
Yunkang does not currently pay a dividend.
To buy shares in Yunkang you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$11.06, shares in Yunkang had a market capitalisation of HK$6.87bn.
Here are the trading details for Yunkang:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2325
Based on an overall assessment of its quality, value and momentum Yunkang is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Yunkang is HK$13.98. That is 26.42% above the last closing price of HK$11.06.
Analysts covering Yunkang currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yunkang. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -14.79%.
As of the last closing price of HK$11.06, shares in Yunkang were trading -7.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yunkang PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$11.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Yunkang's directors